Efectos de los fármacos con acción GLP-1 sobre las comorbilidades o enfermedades relacionadas con obesidad

IF 2.1 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

Medicina Clinica Pub Date : 2025-09-27 DOI:10.1016/j.medcli.2025.107184

Nuria Vilarrasa , Silvia Pellitero

{"title":"Efectos de los fármacos con acción GLP-1 sobre las comorbilidades o enfermedades relacionadas con obesidad","authors":"Nuria Vilarrasa , Silvia Pellitero","doi":"10.1016/j.medcli.2025.107184","DOIUrl":null,"url":null,"abstract":"<div><div>Agents targeting the glucagon-like peptide-1 receptor (GLP-1R) are effective in managing metabolic conditions associated with obesity, such as obstructive sleep apnea (OSA), metabolic dysfunction-associated steatotic liver disease (MASLD), and chronic kidney disease (CKD). In OSA, studies with first generation GLP-1R agonists (ArGLP-1) and co-agonists (GLP-1/GIP) have demonstrated significant improvements in the apnea-hypopnea index and weight reduction. In MASLD, GLP-1RAs and co-agonists (GLP-1/GIP or GLP-1/glucagon) have shown efficacy in reducing hepatic fat, improving fibrosis, and resolving steatohepatitis, with promising results from trials such as ESSENCE and SYNERGY-NASH. In CKD, semaglutide has been associated with a reduction in renal events and slower disease progression. Beyond their metabolic and cardiovascular benefits, these agents represent a comprehensive approach to treating obesity and its complications, with ongoing research exploring their potential indications in chronic inflammatory diseases such as psoriasis and hidradenitis suppurativa.</div></div>","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"165 6","pages":"Article 107184"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina Clinica","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0025775325004129","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Agents targeting the glucagon-like peptide-1 receptor (GLP-1R) are effective in managing metabolic conditions associated with obesity, such as obstructive sleep apnea (OSA), metabolic dysfunction-associated steatotic liver disease (MASLD), and chronic kidney disease (CKD). In OSA, studies with first generation GLP-1R agonists (ArGLP-1) and co-agonists (GLP-1/GIP) have demonstrated significant improvements in the apnea-hypopnea index and weight reduction. In MASLD, GLP-1RAs and co-agonists (GLP-1/GIP or GLP-1/glucagon) have shown efficacy in reducing hepatic fat, improving fibrosis, and resolving steatohepatitis, with promising results from trials such as ESSENCE and SYNERGY-NASH. In CKD, semaglutide has been associated with a reduction in renal events and slower disease progression. Beyond their metabolic and cardiovascular benefits, these agents represent a comprehensive approach to treating obesity and its complications, with ongoing research exploring their potential indications in chronic inflammatory diseases such as psoriasis and hidradenitis suppurativa.

查看原文本刊更多论文

GLP-1药物对肥胖相关疾病或共病的影响

靶向胰高血糖素样肽-1受体（GLP-1R）的药物可有效治疗与肥胖相关的代谢疾病，如阻塞性睡眠呼吸暂停（OSA）、代谢功能障碍相关的脂肪变性肝病（MASLD）和慢性肾脏疾病（CKD）。在OSA中，第一代GLP-1R激动剂（ArGLP-1）和协同激动剂（GLP-1/GIP）的研究表明，在呼吸暂停-低通气指数和体重减轻方面有显著改善。在MASLD中，GLP-1RAs和协同激动剂（GLP-1/GIP或GLP-1/胰高血糖素）已显示出减少肝脏脂肪、改善纤维化和解决脂肪性肝炎的功效，在ESSENCE和SYNERGY-NASH等试验中取得了令人鼓舞的结果。在CKD中，西马鲁肽与肾脏事件的减少和疾病进展的减慢有关。除了代谢和心血管方面的益处，这些药物还代表了一种治疗肥胖及其并发症的综合方法，目前正在进行的研究正在探索它们在慢性炎症性疾病（如牛皮癣和化脓性汗腺炎）中的潜在适应症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicina Clinica 医学-医学：内科

CiteScore

3.10

自引率

5.10%

发文量

295

审稿时长

22 days

期刊介绍： Medicina Clínica, fundada en 1943, es una publicación quincenal dedicada a la promoción de la investigación y de la práctica clínica entre los especialistas de la medicina interna, así como otras especialidades. Son características fundamentales de esta publicación el rigor científico y metodológico de sus artículos, la actualidad de los temas y, sobre todo, su sentido práctico, buscando siempre que la información sea de la mayor utilidad en la práctica clínica.